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Objectives. To determine the utility of routine surveillance MRI in detecting locoregional recurrence following deﬁnitive
chemoradiation in advanced-stage oropharynx carcinoma. Methods. We identiﬁed patients with Stage III-IV oropharynx
carcinoma who were treated with chemoradiation between April 2000 and September 2004 and underwent longitudinal followup
care at our institution. Patient charts were retrospectively reviewed for ﬁndings on MRI surveillance imaging, clinical signs and
symptoms, and recurrence. Results. Forty patients received a total of 229 surveillance MRI scans with a minimum follow-up of
three years (mean of 5.6 scans per patient). Six patients experienced false-positive surveillance studies that resulted in intervention.
Four patients experienced recurrent disease, two of whom had new symptoms or exam ﬁndings that preceded radiographic
identiﬁcation of disease. Surveillance MRI scans identiﬁed recurrent disease in two asymptomatic patients who were salvaged,
one of whom remains free of disease at follow-up. The overall sensitivity and speciﬁcity of the MRI surveillance program were 50
and 83 percent, respectively. The mean charge to each patient for the surveillance program was approximately $10,000 annually.
Conclusion. In oropharyngeal cancer patients who have been treated with chemoradiation, an imaging surveillance program
utilizing MRI produces limited opportunity for successful salvage.
1.Introduction
The exact role of surveillance imaging following treatment
for oropharynx cancer remains undeﬁned. Until recently,
the National Comprehensive Care Network (NCCN) and the
American Head and Neck Society (AHNS) limited imaging
recommendations after treatment of head and neck cancers
to yearly chest radiographs [1, 2]. Despite these guidelines, a
survey of head and neck surgeons conducted by Paniello et
al. found heterogeneity regarding the use of post treatment
locoregional imaging of head and neck cancers, including
advanced imaging for surveillance of disease recurrence [3].
Multiple authors have argued in favor of post-treatment
imaging in head and neck cancers. Studies have demon-
strated that a baseline post-treatment study carries prog-
nostic information regarding locoregional control [4–6]a n d
allows for comparison to subsequent studies, making it pos-
sible to detect tumor recurrences or treatment complications
with more conﬁdence [7]. Nonetheless, the evidence for
periodic routine surveillance imaging is not established [8].
Some authors argue that it may lead to earlier detection
of recurrence allowing for more prompt salvage therapies
and improved long-term outcomes [9]. Others believe that
the longer survival rates reported with surveillance imaging
protocols may be due to lead-time bias [10].
The NCCN recently amended their recommendations to
call for cross-sectional imaging of the primary site and neck
within six months of treatment completion and reimaging
based on clinical signs and symptoms [11]. Commonly
available choices of imaging modality include computed
tomography (CT), magnetic resonance imaging (MRI),
diﬀusion-weighted MRI, positron emission tomography2 International Journal of Otolaryngology
(PET), and PET-CT. Debate continues regarding the relative
v a l u eo fe a c hm o d a l i t y[ 12].
At our institution, MRI has been the preferred modality
for locoregional surveillance after treatment of head and
neck cancers. We previously reported our institutional expe-
rience of patients who underwent intensity-modulated radi-
ation therapy combined with concurrent platinum-based
chemotherapy for Stage III or IV oropharyngeal carcinoma
between April 2000 and September 2004 [13]. This dataset
represents a relatively uniform population of similarly staged
and treated head and neck cancer patients. The purpose
of the current investigation was to determine the utility of
routine surveillance MRI to detect locoregional treatment
failure for advanced-stage oropharyngeal carcinoma treated
with chemoradiation.
2. Methods
A waiver of informed consent was granted by our insti-
tution’s committee on human research to conduct this
retrospective review. We identiﬁed patients with Stage III-IV
oropharyngeal carcinoma who underwent chemoradiation
therapy between April 2000 and September 2004 and
underwent longitudinal follow-up care at the University of
California, San Francisco (UCSF) Comprehensive Cancer
Center. Patients who received clinical and radiographic
follow-up at outside institutions were excluded. Prior to
treatment, all patients underwent complete history and
physical examination, panendoscopy and biopsy, CT or MRI
of the head and neck region, laboratory studies and chest
radiography, dental evaluation, and nutritional, speech and
swallowing evaluation.
Recommendedposttreatmentsurveillanceincludedclin-
ical history and physical examination at a frequency of
every 1-2 months for the ﬁrst year, 2-3 months for the
second year, 3-4 months for the third and fourth years,
and 6 months for the ﬁfth year. Chest radiograph and
thyroid function studies were obtained yearly. All patients
underwent a post treatment baseline MRI approximately
two months after completion of chemoradiation therapy.
Surveillance MRIs were performed approximately every 3-4
months in the ﬁrst year post treatment and approximately
every 6 months in subsequent years. All patients included in
this study adhered closely to this protocol. MRI sequences
included axial, coronal, and sagittal pregadolinium T1; fat-
saturated axial fast spin echo T2; and fat-saturated axial
and coronal postgadolinium T1. Adjunctive studies, such
as PET/CT scans, were performed as clinical evaluation
dictated, but were not speciﬁcally analyzed in this study.
References to radiographic investigations imply MRI scans
for the purposes of this study.
Patient charts were retrospectively reviewed for disease
staging, treatment and surveillance information, and recur-
rence. For patients who experienced locoregional failure,
charts were reviewed for description of recurrence, imaging
and physical exam ﬁndings, and patient symptomatology at
time of diagnosis. Time until treatment failure was deﬁned
as the diﬀerence from chemoradiation completion until
radiographic or deﬁnitive clinical evidence of recurrence,
Table 1: Distribution of patients by the 2002 American Joint
Committee on Cancer Staging Classiﬁcation.
S t a g e N 0N 1N 2N 3T o t a l
T 10151 7
T2 0 6 12 2 20
T 324401 0
T 41110 3
Total 3 12 22 3 40
whichever came ﬁrst. Radiographic failure was deﬁned by
language within the ﬁnalized MRI report speciﬁcally impli-
catingthepresenceoftumororsuggestingtumorpresenceby
interval growth or concerning radiographic features such as
signal characteristics. Additionally, for patients with clinical
symptoms or questionable ﬁndings on MRI scans, review at
tumor board by the multidisciplinary head and neck team
routinely occurred, including the presence of an experienced
head and neck radiologist. These deﬁnitions were then
used to calculate MRI diagnostic accuracy measurements,
including sensitivity, speciﬁcity, positive predictive value,
and negative predictive value. Disease persistence versus
recurrence was deﬁned as disease identiﬁed within or after
a 3-month-time frame post treatment, respectively. Invasive
procedures performed within 4 months of chemoradiation
completion, such as neck dissection, were considered to be
an extension of primary treatment rather than investigations
into disease recurrence.
Expense estimates were obtained from our institution’s
Department of Radiology. We based our estimates from
current charge data for an MRI neck with gadolinium, which
was $4,942 as of April, 2010.
3. Results
3.1. Patient Characteristics. Seventy-one patients with
advanced (Stage III or IV) oropharynx carcinoma were
treated with concurrent chemoradiation at UCSF between
April 2000 and September 2004. Forty-three patients met
our inclusion criteria of clinical and radiologic MRI imaging
surveillance follow-up performed at our institution. Three
of these 43 patients had malignant disease identiﬁed within
three months of completion of their treatment and were
considered to have persistent disease. The remaining 40
patients were considered to have been rendered disease free
by their initial treatment and were the focus of the remainder
of our analysis.
Our study group consisted of 35 men and 5 women with
a median age of 58 years (range, 41–81 years). The primary
site of disease included base of tongue (27), tonsil (11), and
oropharyngeal wall (2). Table 1 provides the T-stage and
N-stage distributions of the patients according to the 2002
AJCC staging classiﬁcation system. The disease was Stage III
in 11 patients (28%) and Stage IV in 29 patients (72%).
Four patients experienced locoregional failure after
an initial complete clinical and radiographic response to
treatment. Three additional patients experienced distant
metastatic disease without locoregional failure, identiﬁed atInternational Journal of Otolaryngology 3
Table 2: Patient characteristics, primary site, and stage of locore-
gional and distant treatment failures.
Locoregional recurrent disease
Number of patients 4
Age, years 65 (range, 55–81)
Sex Male (4)
Primary site Base of tongue (4)
TMN stage T1N2b (1), T2N2b (2), and
T3N2b (1)
Distant metastases
Number of patients 3
Age 62 (range, 52–68)
Sex Male (3)
Primary site Base of tongue (3)
TMN stage T2N1 (2), T2N2c (1)
a mean of 11 months post treatment (range, 4–20 months).
Table 2 displays patient characteristics for these patients.
3.2. Locoregional Recurrent Disease. Among the four patients
with locoregional recurrence following an initial complete
treatment response, two experienced local failure and two
experienced regional failure. Two of the four patients
experienced recurrence within 12 months of completing
chemoradiation. As shown in Table 3, the mean time
until detection of recurrence was 20.3 months (range, 5–40
months).
The physical exam ﬁndings and patient symptomatology
of the 4 patients with locoregional recurrence are sum-
marized in Table 4. Surveillance MRI imaging identiﬁed
recurrent disease in two completely asymptomatic patients
(patients 1, 4). Routine MRI scans revealed a new, enhancing
mass in the tongue base (patient 1) and a cluster of
enlarged level II nodes with focal necrosis (patient 4). The
ﬁrst patient (patient 1) was found by MRI to have cancer
recurrence ﬁve months post chemoradiation and underwent
salvage resection with glossectomy and modiﬁed radical
neck dissection, but died of disease within three months of
surgery. The second patient (patient 4) experienced isolated
cervical nodal recurrence 26 months after completion of
treatment and underwent a salvage neck dissection; this
patient remains free of disease at two-year follow-up. Both
patients were undergoing regular clinical follow-up; patients
1 and 4 had negative head & neck examinations ﬁve and
16 weeks prior to MRI detection of tumor recurrence,
respectively.
Two patients (patients 2, 3) exhibited signs and/or symp-
toms prior to MRI evidence of disease. Symptoms included
pharyngeal discomfort with foreign body sensation (patient
2) and worsening unilateral otalgia (patient 3). The ﬁrst
patient (patient 2) had concerning physical exam ﬁndings in
the form of tongue base mucosal irregularity; a subsequent
MRI scan was suspicious for locally recurrent disease. This
patient underwent brachytherapy at the site of recurrence
and remained free of disease at over two-year follow-up. The
other patient (patient 3) informed his physician of otalgia
at a regularly scheduled clinic follow-up; a new, enlarging
neck mass was noted which was subsequently conﬁrmed on
ﬁne-needle aspiration biopsy. This patient (patient 3) was
treated with additional chemotherapy, but ultimately died of
progressive cervical nodal disease.
3.3. Surveillance Imaging. A total of 229 MRI surveillance
imaging studies were performed (a mean of 5.6 studies per
patient; an average of 2.0 studies per patient-year). The four
patients with locoregional recurrence underwent a total of
23 studies, an average of 5.8 per patient (range, 3–9 studies).
The overall sensitivity and speciﬁcity of the MRI surveillance
program for advanced oropharynx carcinoma were 50 and
83 percent, respectively (Table 5). The positive predictive
value was 25% and the negative predictive value was 94%.
To perform a simple cost analysis of our MRI surveillance
program, we used the standard charge at our institution for
an MRI of the neck with gadolinium, which was $4,942
in April 2010. The total expense for the MRI surveillance
program approximated $1.13 million and averaged $28,293
per patient. The average annual expense of this program was
$9,794 per patient.
Six patients experienced false-positive imaging results,
all of whom underwent interventions to validate the sus-
picious imaging scans. All patients had normal physical
exams and no clinical concerns at the time of positive
MRI ﬁndings. Four patients underwent panendoscopy with
biopsies, and two patients underwent ﬁne-needle aspiration
biopsies. For the 4 patients with concerning ﬁndings at
the primary site, MRI demonstrated concerning asymmetry
with enhancement, T2 prolongation, or both; all 4 MRI
reports raised the possibility of tumor recurrence and
suggested direct visualization, biopsy, further radiographic
imaging, or a combination thereof. MRI studies for the
two patients that underwent ﬁne needle aspiration biopsies
revealed enlarging or persistently large lymph nodes. MRI
reports for these 2 patients both suggested the possibility
of malignancy in lymph nodes. None of these six patients
complained of new or worsening symptomatology at the
time of radiographic study, nor did any display concerning
physical exam ﬁndings. No patient suﬀered complications
from the testing procedures, and none has subsequently
shown any evidence of recurrence with a minimum of 6-
month follow-up.
4. Discussion
Among our cohort of patients with advanced-stage orophar-
ynx carcinoma treated with chemoradiation therapy, a
surveillance imaging program with MRI was equal to patient
symptomatology and physical examination in detecting can-
cer recurrence. A total of 229 MRI scans were performed to
identify two asymptomatic patients with cancer recurrence.
Despite early detection and salvage therapy in both patients,
only one patient achieved a disease-free state. This outcome
mirrored the identiﬁcation of cancer recurrence via clinical
history and physical examination, in which two patients
were identiﬁed, one of whom achieved a disease-free state4 International Journal of Otolaryngology
Table 3: Primary site, staging, time to recurrence, and treatment outcome of locoregional failures.
Patient no. Primary site Stage Site of failure Time to failure detection, mon. Salvage therapy Clinical status
Locoregional recurrent disease
1 BOT T2N2b Local 5 Surgery DOD
2 BOT T3N2b Local 40 Brachytherapy Alive
∗
3 BOT T1N2b Regional 11 Chemotherapy DOD
4 BOT T2N2b Regional 26 Surgery Alive
†
DOD, died of disease
∗No evidence of disease at 26 months after high-dose-rate brachytherapy and chemotherapy
† No evidence of disease at 25 months after neck dissection
Table 4: Patient symptomatology and physical exam ﬁndings prior
to radiographic evidence of failure.
Patient
no. Symptoms Physical exam
No. of MRIs
performed until
detection of
recurrence
Locoregional recurrent disease
1 None None 2
2 Throat fullness Tongue base
irregularity 9
3O t a l g i a N e w n e c k m a s s 3
4 None None 6
Table 5: MRI surveillance program sensitivity and speciﬁcity.
Recurrent disease detected by imaging (patients) 2
Recurrent disease not detected by imaging (patients) 2
Nonrecurrent disease with false-positive study (patients) 6
Nonrecurrent disease with negative studies (patients) 30
Sensitivity (percent) 50
Speciﬁcity (percent) 83
Positive predictive value (percent) 25
Negative predictive value (percent) 94
following salvage therapy. The overall sensitivity of our
radiographic surveillance program utilizing MRI was 50
percent. The overall sensitivity of detecting recurrence based
on patient symptomatology and physical examination was
also 50 percent.
Oropharynx carcinoma has several unique qualities that
likelycontributedtoourstudyresults.Theanatomiclocation
of the oropharynx is not easily accessible for physical
examination, thus increasing the potential for radiologic
imaging to detect subclinical recurrence. On the other hand,
current chemoradiation treatment protocols for oropharynx
cancers, particularly HPV-related tumors in nonsmokers,
can achieve low recurrence and second primary rates.
As previously reported, among our study population of
advancedoropharynxcarcinomapatientswhowererendered
disease free by initial concurrent chemoradiation treatment,
lessthan10%suﬀered locoregional recurrence [13].Thislow
recurrence rate likely reduces the beneﬁt of any surveillance
program as compared to a similar program for a cancer site
with a worse prognosis.
The recent literature on imaging for head and neck
squamous cell carcinoma (HNSCC) reveals a preponderance
of studies on PET and PET/CT rather than other modalities
such as MRI, CT, and ultrasound. PET has been reported
to be a highly sensitive technique for detection of HNSCC
in the postchemoradiation setting [14] .Ar e c e n tr e p o r t
of MRI for the detection of clinically suspected persistent
or recurrent HNSCC showed similar high sensitivity [15].
While MRI provides the superior soft-tissue delineation
and anatomic detail, the application of PET for cancer
detection is unique in relying on diﬀerential metabolism of
malignant versus benign tissue. There have been few studies
comparing the eﬃcacy of PET versus MRI for the detection
of recurrent HNSCC, and the best imaging modality for
the detection of recurrent HNSCC remains undetermined.
When the patients in our study were undergoing treatment
and follow-up, PET/CT had only been recently introduced
to our institution. PET/CT was only used as an adjunctive
tool to MRI in our cohort and did not inﬂuence the
frequency or timing of detection of recurrences by MRI.
We are currently comparing the utility of PET/CT versus
MRI scans for oropharyngeal cancer surveillance. However,
given the high locoregional control rates for oropharynx
cancer that we continue to achieve with our concurrent
chemoradiation protocols, we believe it is doubtful that
we will see substantially diﬀerent results with PET/CT
compared to what we observed with MRI in the current
investigation.
Our study is limited by its overall small cohort, sin-
gle institution status, and retrospective nature. Regardless,
our results suggest that, for advanced-stage oropharyngeal
carcinoma treated with chemoradiation, a routine imag-
ing surveillance program with MRI oﬀers limited beneﬁt
in detecting cancer recurrence and improving long-term
outcome when compared to standard clinical follow-up.
This assessment is further bolstered when considering the
overall expense of a routine advanced radiographic imag-
ing program, which averaged nearly $10,000 per patient
annually, and the potential patient morbidity resultant from
interventions initiated by ﬁndings identiﬁed by the imaging
program. Six patients in our cohort experienced a false-
positive imaging study, which led to invasive procedures
to evaluate the imaging ﬁndings. Although there were no
complications associated with these interventions, there can
be signiﬁcant emotional stress associated with a “positive”
radiologic imaging report.International Journal of Otolaryngology 5
We acknowledge that routine surveillance imaging may
be of beneﬁt in detecting recurrence in a speciﬁc subset of
patientsathighriskforrecurrence,butwithinthelimitations
of our study, such a cohort could not be identiﬁed. Analysis
of larger, multi-institutional patient populations directed at
this question could help further deﬁne the beneﬁts and lim-
itations of a routine imaging surveillance program following
chemoradiation for advanced head and neck cancer.
5. Conclusion
In patients with advanced-stage oropharyngeal carcinoma
treated with chemoradiation, this study suggests limited
beneﬁt from routine surveillance MRI scans for detecting
cancer recurrence as compared to close clinical follow-up.
Further analysis is needed to identify patients at highest
risk of recurrence who would most beneﬁt from routine
surveillance imaging.
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